FDA Alerts Public To Ongoing Safety Review Of Orlistat In GSK, Roche Drugs

By The Tan Sheet / “The Tan Sheet” Aug. 31, 2009, Vol. 17, No. 035
OTCs / Word Count: 674 / Article # 05170350004

Executive Summary

FDA's announcement it is investigating a possible risk of liver injury related to orlistat - the active ingredient in Roche Pharmaceuticals' prescription weight-loss drug Xenical and GlaxoSmithKline's OTC alli - could threaten short-term sales

Purchase this Article

$35.00 Buy Now

For $35.00, purchase this 674-word article and receive immediate online access. 100% Satisfaction Guarantee.

View a complete sample article »

Already a Subscriber?

Log in for complete access.

Questions?

Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.

Log In

Email Address

Password

Remember Me

Forgot your password?

Don’t Have an Account?

If your employer has a site license, create your account to begin using it. Simply click ‘Create An Account’ button below to register now.

Otherwise, please explore our free content subscriptions.

Create an account

Enter the email address associated with your account and a temporary password will be sent to you.

Email Address

Need help? Contact us at (800) 332-2181, +1 (908) 547-2159, or custcare@elsevier.com

Email Article

* Required field

* To:

For multiple recipients, separate email addresses with a semi-colon.

* Your Name:

* Your Email:

Subject: FDA Alerts Public To Ongoing Safety Review Of Orlistat In GSK, Roche Drugs

* Add a personalized message to your email:

Please Note: Only individuals with subscriptions to “The Tan Sheet” will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.

or Cancel

FDA Alerts Public To Ongoing Safety Review Of Orlistat In GSK, Roche Drugs

Executive Summary

Purchase this Article

Already a Subscriber?

Questions?

Related Articles: 9

Elsevier Business Intelligence Publications

Offers & Events

Topics Covered in this Article

Email Article